Eli Lilly & Co. vs. Mirum Pharmaceuticals, Inc. Common Stock
Eli Lilly & Co. and Mirum Pharmaceuticals, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| LLY | MIRM | |
|---|---|---|
| Market Cap | $1.03 trillion | $6.53 billion |
| Revenue (TTM) | $79.67 billion | $618.07 million |
| Net Income (TTM) | $26.71 billion | $-860,207,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | MIRM | |
|---|---|---|
| P/E Ratio | 38.69 | — |
| Price / Book | 30.32 | -626.83 |
| Price / Sales | 12.89 | 10.57 |
MIRM leads on 2 of 2 valuation factors.
Profitability
| LLY | MIRM | |
|---|---|---|
| Net Margin | 33.53% | -139.18% |
| Return on Equity | 78.84% | 8253.76% |
LLY and MIRM split the profitability factors evenly.
Dividend
| LLY | MIRM | |
|---|---|---|
| Dividend Yield | 0.60% | — |
| Payout Ratio | 23.23 | — |
LLY and MIRM split the dividend factors evenly.
Risk & Sentiment
| LLY | MIRM | |
|---|---|---|
| Short Interest | 1.29% | 0.09% |
MIRM leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, MIRM overview, MIRM financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.